Garima Pathak1, Amit Upadhyay, Umesh Pathak, Deepak Chawla, Sneh P Goel. 1. Department of Pediatrics, LLRM Medical College, Meerut;Department of Pediatrics, Government Medical College, Chandigarh; and Department of Pediatrics, Subharti Medical College, Meerut, UP, India. Correspondence to: Dr Amit Upadhyay, Department of Pediatrics, LLRM Medical College, Meerut, India. anuamit7@rediffmail.com.
Abstract
OBJECTIVE: To compare the efficacy of phenobarbitone and phenytoin for treatment of neonatal seizures in term and near-term neonates. DESIGN: Open labeled randomized controlled trial. SETTING:Neonatal intensive care unit of a level II unit from India, from November 2008 to September 2009. PARTICIPANTS: All term and late pre-term neonates admitted with clinically apparent seizures and not having any transient metabolic disorders (hypoglycemia or hypocalcemia) were randomly assigned. INTERVENTION: Phenobarbitone (n=54) or phenytoin (n=55) intravenously 20 mg/kg/dose over 20-30 min. Neonates whose seizures were not controlled by the assigned drug were then crossed over to be treated with other drug in same dose. PRIMARY OUTCOME VARIABLE: Clinical control of seizures (seizure free period of 24 hours after giving anticonvulsant). RESULTS: Baseline characteristics including mean birthweight, gestation age and sex were comparable in both groups. Seizures were controlled in 8 of the 55 (14.5%) neonates who received phenytoin, as compared to 39 of 54 (72.2%) neonates who received phenobarbitone (P <0.001). In babies not responding to assigned drugs, after cross-over to the other drug, seizure control was achieved in 44/55 (80%) of the neonates assigned to receive phenytoin first as compared to 49/54 (91%) of those assigned to receive phenobarbitone first (P=0.014). After maximum dose of phenobarbitoneseizures were controlled in 49/55(89%) in phenytoin group and 52/54 (96%) in phenobarbitone group (P<0.05). CONCLUSIONS:Phenobarbitone is more efficacious than phenytoin in control of clinical seizures in term or near-term neonates, irrespective of etiology. To evaluate serum vascular endothelial growth factor (VEGF) levels in children with acute lymphoblastic leukemia (ALL) during the induction phase of chemotherapy.
RCT Entities:
OBJECTIVE: To compare the efficacy of phenobarbitone and phenytoin for treatment of neonatal seizures in term and near-term neonates. DESIGN: Open labeled randomized controlled trial. SETTING: Neonatal intensive care unit of a level II unit from India, from November 2008 to September 2009. PARTICIPANTS: All term and late pre-term neonates admitted with clinically apparent seizures and not having any transient metabolic disorders (hypoglycemia or hypocalcemia) were randomly assigned. INTERVENTION: Phenobarbitone (n=54) or phenytoin (n=55) intravenously 20 mg/kg/dose over 20-30 min. Neonates whose seizures were not controlled by the assigned drug were then crossed over to be treated with other drug in same dose. PRIMARY OUTCOME VARIABLE: Clinical control of seizures (seizure free period of 24 hours after giving anticonvulsant). RESULTS: Baseline characteristics including mean birthweight, gestation age and sex were comparable in both groups. Seizures were controlled in 8 of the 55 (14.5%) neonates who received phenytoin, as compared to 39 of 54 (72.2%) neonates who received phenobarbitone (P <0.001). In babies not responding to assigned drugs, after cross-over to the other drug, seizure control was achieved in 44/55 (80%) of the neonates assigned to receive phenytoin first as compared to 49/54 (91%) of those assigned to receive phenobarbitone first (P=0.014). After maximum dose of phenobarbitoneseizures were controlled in 49/55(89%) in phenytoin group and 52/54 (96%) in phenobarbitone group (P<0.05). CONCLUSIONS:Phenobarbitone is more efficacious than phenytoin in control of clinical seizures in term or near-term neonates, irrespective of etiology. To evaluate serum vascular endothelial growth factor (VEGF) levels in children with acute lymphoblastic leukemia (ALL) during the induction phase of chemotherapy.
Authors: Céline Thibault; Shavonne L Massey; Nicholas S Abend; Maryam Y Naim; Alexandra Zoraian; Athena F Zuppa Journal: J Clin Pharmacol Date: 2020-09-22 Impact factor: 3.126